 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Ligand Pharmaceuticals Incorporated
 |
Ligand Pharmaceuticals Incorporated |
 |
 |
 |
PROFILE |
 |
Ligand Pharmaceuticals is receptive to new ideas. The company develops small-molecule drugs that interact with hormone-activated intracellular receptors. Four of its products have received regulatory approval in the US or Europe: Panretin (AIDS-related Kaposi's sarcoma) and ONTAK (T-cell lymphoma) and Targretin (gel and oral formulations to treat skin lesions related to T-cell lymphoma). Its drug pipeline includes candidates targeting breast, renal, lung, and other cancers, as well as psoriasis, eczema, and acne. The firm also makes money from royalties and research alliances with such companies as Elan (which owns more than 20% of Ligand), Eli Lilly, Abbott Laboratories, and Pfizer.
COMPETITION |
 |
Agouron Pharmaceuticals, Inc. (dossier)
Gilead Sciences, Inc. (GILD)
IDEC Pharmaceuticals Corporation (IDPH)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 48.10
1-Yr. Sales Growth: 17.6%
Employees: 356
Revenue per employee: $135,112.36
KEY PEOPLE |
 |
David E. Robinson
CEO
Paul V. Maier
CFO
CONTACT INFO |
 |
10275 Science Center Dr.
San Diego, CA 92121
US
Phone: 858-550-7500
Fax: 858-550-7506
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |